Onconova Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | (89 %) | (2 %) | - | - | 1 % | (23 %) | 70 % |
| EBITDA | (24.8m) | (16.8m) | (19.6m) | (20.3m) | (23.5m) | (28.6m) | (33.2m) |
| % EBITDA margin | (10729 %) | (7441 %) | (8685 %) | (8974 %) | (10307 %) | (16186 %) | (11067 %) |
| Profit | (25.2m) | (16.2m) | (19.0m) | (18.9m) | (141m) | (30.2m) | (33.0m) |
| % profit margin | (10890 %) | (7152 %) | (8391 %) | (8384 %) | (61886 %) | (17068 %) | (11000 %) |
| EV / revenue | 372.9x | 235.7x | 59.8x | 69.3x | 41.1x | 53.1x | 31.3x |
| EV / EBITDA | -3.5x | -3.2x | -0.7x | -0.8x | -0.4x | -0.3x | -0.3x |
| R&D budget | 16.9m | 7.3m | 11.4m | 11.4m | - | - | - |
| R&D % of revenue | 7315 % | 3229 % | 5047 % | 5058 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | - | |
| N/A | $19.2m | Late VC | |
| N/A | $11.7m | Late VC | |
| N/A | $7.1m | Early VC | |
| N/A | $50.0m | Late VC | |
| N/A | N/A | IPO | |
| N/A | $1.5m | Early VC | |
| N/A | $1.3m | Post IPO Equity | |
$8.7m | Post IPO Equity | ||
| N/A | $21.0m | Post IPO Equity | |
| Total Funding | AUD138m | ||
Related Content
Recent News about Onconova Therapeutics
EditOnconova Therapeutics, Inc. is a Phase 3 clinical stage biopharmaceutical company dedicated to discovering and developing novel small molecule drug candidates aimed at treating cancer. The company leverages a proprietary chemistry platform to create a pipeline of targeted anti-cancer agents designed to interfere with specific cellular pathways crucial to cancer cells, while minimizing harm to normal cells. Onconova's primary clients include healthcare providers and institutions involved in cancer treatment and research. Operating in the biopharmaceutical market, Onconova's business model revolves around advancing its drug candidates through clinical trials, securing regulatory approvals, and ultimately commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved drugs.
Keywords: biopharmaceutical, cancer treatment, small molecule drugs, clinical trials, proprietary chemistry, targeted therapy, healthcare providers, regulatory approvals, licensing agreements, commercialization.
